Lung cancer is the most common cause of cancer death for both women and men. There is therefore a pressing need to improve lung cancer therapy and prevention. This is the subject of this new NIH R01 application in which we now seek to elucidate a previously unrecognized pathway that we found as clinically-tractable in combating lung cancer. Termed anaphase catastrophe, this is caused by targeting the cyclin E-Cdk2 pathway in aneuploidy cancer cells. Neoplastic cells are genetically unstable; strategies that target genome instability are attractive ways to disrupt tumor cell growth and potentially spare normal diploid cells. Chromosome instability (CIN) is genome instability via mitotic defects that increase chromosome mis-segregation. CIN is caused by extra centrosomes that disrupt bipolar spindle assembly needed for faithful chromosome segregation. We found that Cdk2 inhibition prevents centrosome clustering and forces chromosomes to segregate into multiple daughter cancer cells. This triggers apoptosis in aneuploid cells, including lung cancer cells, as will be studied here. Using a robotic cell-based drug screening platform linked to a genetic database, KRAS mutant lung cancer (representing an unmet medical need) cells were exquisitely sensitive to Cdk2 inhibition because they exhibit anaphase catastrophe and apoptosis. CP110 is a centrosome protein and direct Cdk2 phosphorylation target that regulates centrosome clustering. Our hypothesis is: CP110 is the centrosome protein responsible for anaphase catastrophe. Our interdisciplinary team has a long track record of productive collaboration. We have assembled for this work selective Cdk2 inhibitors, clinically-relevant transgenic cyclin E-driven and KRAS-driven mouse lung cancer models and their derived cell lines. A large human lung cancer cell line panel is available as is a paired normal- malignant lung tissue array linked to a clinical database. Our team will use these resources to interrogate these Specific Aims to: (1) learn if CP110 is the critical target of Cdk2 inhibition that antagonizs centrosome clustering and promotes multipolar anaphase to trigger lung cancer cell death; (2) elucidate whether CP110 is the critical mediator of Cdk2-dependent anti-neoplastic effects in lung cancer cells; and (3) establish the biological and clinical relevance of this work using clinically- predictive in vitro, transgenic, and normal-malignant lung tissue banks. Successful completion of these aims would provide a new way to confront lung cancer, the most common cause of cancer death for men and women. This would ultimately identify which lung cancer cases are amenable to Cdk2 inhibition.

Public Health Relevance

Lung cancer is the most common cause of cancer death for men and women; new ways to combat lung cancer are needed. This new NIH R0-1 application explores this need via a novel target that we found engaged by Cdk2 inhibition. Known as anaphase catastrophe, we explore here how this triggers apoptosis in aneuploid lung cancers, including those with KRAS mutations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA190722-01
Application #
8800790
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Forry, Suzanne L
Project Start
2015-04-01
Project End
2020-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$381,425
Indirect Cost
$139,498
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Mustachio, Lisa Maria; Lu, Yun; Kawakami, Masanori et al. (2018) Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. Cancer Res 78:587-592
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175
Kawakami, Masanori; Mustachio, Lisa Maria; Liu, Xi et al. (2018) Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers. Mol Cancer Ther 17:724-731
Kawakami, Masanori; Mustachio, Lisa Maria; Zheng, Lin et al. (2018) Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A 115:1913-1918
Mustachio, Lisa Maria; Lu, Yun; Tafe, Laura J et al. (2017) Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Mol Cancer Res 15:905-914
Mustachio, Lisa Maria; Kawakami, Masanori; Lu, Yun et al. (2017) The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget 8:3-14
Sepesi, Boris; Gold, Kathryn A; Correa, Arlene M et al. (2017) The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. J Thorac Oncol 12:1280-1287
Yim, Christina Y; Bikorimana, Emmanuel; Khan, Ema et al. (2017) G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. Cell Cycle 16:2146-2155
Kawakami, Masanori; Mustachio, Lisa Maria; Rodriguez-Canales, Jaime et al. (2017) Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109:
Yim, Christina Y; Sekula, David J; Hever-Jardine, Mary P et al. (2016) G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Res 76:1204-13

Showing the most recent 10 out of 18 publications